BackViracta Therapeutics Overview

Viracta Therapeutics Long Term Debt

Latest long-term debt for VIRX: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

Viracta Therapeutics Long Term Debt History

Loading

Viracta Therapeutics vs. peers: Long Term Debt Comparison

Loading

Viracta Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Viracta Therapeutics (VIRX) FAQ

The latest long-term debt for VIRX is $0 as of September 2024. In the prior-year period, the figure was $0. Investors often review this figure alongside Viracta Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VIRX's long-term debt moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Viracta Therapeutics's operating scale or balance-sheet position.

A long-term debt figure of $0 for VIRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting VIRX's long-term debt ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Viracta Therapeutics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.